Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2018-01-09
Target enrollment:
Participant gender:
Summary
This is a Phase II study of docetaxel, bevacizumab, prednisone and thalidomide in patients
with androgen independent metastatic prostate cancer who are previously untreated with
chemotherapy. The primary objective of this study is to determine if the combination of
docetaxel, thalidomide and bevacizumab is able to be associated with a sufficiently high
proportion of patients with a prostate-specific antigen (PSA) response to be worthy of
further investigation in metastatic prostate cancer. We will also be looking at multiple
secondary endpoints. These will include possible pharmacokinetic interactions among the study
agents, potential correlation between patient genotype and efficacy of treatment. We will
also be looking for circulating tumor cells in blood before and after treatment. Additionally
we will be monitoring the tolerability of the regimen and survival duration as endpoints as
well. We hope to use this trial to build on the promising results seen in our
thalidomide/docetaxel protocol where there was a significant PSA decline and a trend toward
survival benefit.